PMID- 11824947
OWN - NLM
STAT- MEDLINE
DCOM- 20020702
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 29
IP  - 1
DP  - 2002 Jan
TI  - Successful short term treatment of severe undifferentiated spondyloarthropathy 
      with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
PG  - 118-22
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) has been detected in 
      sacroiliac joints of patients with spondyloarthropathies (SpA). Anti-TNF-a 
      therapy has been efficacious in patients with active ankylosing spondylitis (AS) 
      and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in 
      undifferentiated SpA (uSpA) are also limited. We tested the efficacy of the 
      monoclonal anti-TNF-alpha antibody infliximab in patients with active and severe 
      uSpA in an open observation trial. METHODS: Six patients with uSpA were treated 
      with 3 infusions of infliximab in a dosage of 3 (n = 3) or 5 mg/kg (n = 3) at 
      Weeks 0, 2, and 6. The total observational period was 12 weeks. The Bath AS 
      Disease Activity Index (BASDAI), the Functional Index (BASFI), pain on a visual 
      analog scale, the Bath AS Metrology Index (BASMI), and quality of life (SF-36) 
      were assessed before, during, and after therapy. RESULTS: Significant improvement 
      at Day 1 after the first infusion lasting until Week 12 was reported by 5/6 
      patients. Improvement of > or = 50% in all activity, function, pain, and swollen 
      joint scores was observed in the patients taking 5 mg/kg. The 3 mg/kg dose was 
      less effective, resulting in > or = 15% improvement in outcome variables. 
      Peripheral arthritis, enthesitis, and spinal symptoms improved equally. 
      C-reactive protein dropped in 4 patients. Health related quality of life 
      increased. No serious side effects or infections occurred. CONCLUSION: These 
      observations suggest that anti-TNF-alpha therapy has significant short term 
      efficacy in patients with severe uSpA.
FAU - Brandt, Jan
AU  - Brandt J
AD  - Department of Gastroenterology and Rheumatology, Benjamin Franklin Hospital, Free 
      University Berlin, Germany.
FAU - Haibel, Hildrun
AU  - Haibel H
FAU - Reddig, Jaqueline
AU  - Reddig J
FAU - Sieper, Joachim
AU  - Sieper J
FAU - Braun, Jurgen
AU  - Braun J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - C-Reactive Protein/immunology/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Edema/drug therapy/immunology/pathology
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Quality of Life/psychology
MH  - Recovery of Function/drug effects/immunology
MH  - Spondylarthropathies/*drug therapy/immunology/physiopathology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology/metabolism
MH  - Zygapophyseal Joint/*drug effects/immunology/pathology
EDAT- 2002/02/05 10:00
MHDA- 2002/07/03 10:01
CRDT- 2002/02/05 10:00
PHST- 2002/02/05 10:00 [pubmed]
PHST- 2002/07/03 10:01 [medline]
PHST- 2002/02/05 10:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 2002 Jan;29(1):118-22.